Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

William J. Gradishar, MD
Published: Tuesday, Oct 17, 2017



William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Trastuzumab (Herceptin) is used in different settings in the treatment of patients with HER2-positive breast cancer.

There is a trend forming, says Gradishar, as dual HER2-targeting is being used first in the preoperative, postoperative, and early in the sequence for patients with metastatic disease.
 


William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Trastuzumab (Herceptin) is used in different settings in the treatment of patients with HER2-positive breast cancer.

There is a trend forming, says Gradishar, as dual HER2-targeting is being used first in the preoperative, postoperative, and early in the sequence for patients with metastatic disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x